Report Code: TIPRE00003527 | No. of Pages: 150 | Category: Medical Device | Status: Prebook
The increasing incidence of chronic diseases, including hypertension, hyperlipidemia, and diabetes, has contributed to the growth of the stroke management market. Hypertension is the leading risk factor for stroke as blood pressure higher than 140/90mmHg can damage the blood vessels that supply blood to the brain. Furthermore, diabetes is also a major cause of stroke. As per the American Stroke Association, people with diabetes have twice the chance of having a stroke, and may also witness the early onset of stroke. Further, within every two minutes, an adult with diabetes is hospitalized due to stroke in US, as per the same data. As a result, the market leaders are working to develop innovative treatments for stroke, and a wide variety of new drugs and devices are under investigation for treatment and diagnosis of all major types of strokes, and many of them are expected to receive approval in the near future. For instance, in September 2020, Johnson & Johnson announced the launch of Cerenovus Stroke Solutions, which consists of three devices that can assist physicians in removing clots. Furthermore, in August 2021, MicroTransponder Inc. received FDA approval for Vivistim System, a first-of-its-kind stroke rehabilitation system, for the treatment of moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.
|Market Size Value in||US$ 33.48 Billion in 2021|
|Market Size Value by||US$ 55.37 Billion by 2028|
|Growth rate||CAGR of 7.5% from 2022 to 2028|
|No. of Pages||150|
|Historical data available||Yes|
|Segments covered||Type, and Application|
|Regional scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Country scope||US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
North America dominated the stroke management market with ~37% share in 2021. The market growth in the region is majorly attributed to the presence of a huge population with chronic disorders along with the presence of leading market players such as Abbott Laboratories, B Braun Melsungen AG, Boston Scientific Corporation, Bristol Myers Squibb Co., Cardinal Health Inc., and General Electric Company. The below figure showcases the revenue growth trend in the North America stroke management market:
The report analyzes factors, such as drivers, restraints, opportunities, and future trends, that impact the stroke management market. It also provides an exhaustive PEST analysis of the factors affecting the market.
The COVID-19 pandemic resulted in the increased demand for stroke management drugs such as Alteplase, Clopidogrel, and Atorvastatin as the prevalence of stroke increased due to the spread of SARS-CoV-2. This led to a high volume of orders among drug manufacturers, resulting in a higher production volume. As a result, the product profit of various drug component manufacturers increased. Thus, the procurement of drug components grew during the initial phase of the pandemic, thereby boosting the growth of the global stroke management market.
Rising awareness about stroke resulted in a sudden rise in the diagnostic rates of the disease, which ultimately increased the demand for stroke targeting drugs such as Ticagrelor, Alteplase, and Clopidogrel. The recombinant tissue plasmogen activators are the most effective treatment for ischemic stroke and are currently prescribed as first-line treatment. As a result, the procurement of recombinant tissue plasmogen activators has increased, which is bolstering the stroke management market.
The report also includes the profiles of major stroke management companies, along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information for the last three years, and key development in the past five years. The list of a few companies engaged in the stroke management market is mentioned below:
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the current study.
The List of Companies
1. Abbott Laboratories
2. B Braun Melsungen AG
3. Boston Scientific Corp.
4. Bristol-Myers Squibb
5. Cardinal Health
6. Medtronic Plc.
7. GlaxoSmithKline Plc.
8. GE Healthcare
10. Koninklijke Philips N.V.